GLP-1 Drug Shortages: How Weight Loss Demand Impacts Diabetes Patients
Off-label prescribing of GLP-1 diabetes drugs for weight loss created supply shortages that made it harder for diabetes patients to access their medications.
Quick Facts
What This Study Found
Semaglutide outperformed dulaglutide in both HbA1c reduction and weight loss, making it the most sought-after GLP-1 drug. Clinicians began prescribing Ozempic (semaglutide for diabetes) off-label for weight loss, even though Wegovy (semaglutide for weight) existed. This drove shortages.
Insurance companies responded by requiring prior authorizations proving a type 2 diabetes diagnosis before covering these drugs. The commentary notes that most insurance plans still do not cover GLP-1 drugs solely for weight management, pushing weight-loss demand onto the diabetes supply chain.
Key Numbers
- Semaglutide: FDA-approved for diabetes (Ozempic) and weight loss (Wegovy)
- Dulaglutide: outperformed by semaglutide in HbA1c and weight reduction
- Tirzepatide: FDA-approved for diabetes May 2022
- Insurance now requires prior authorization proving T2DM diagnosis
How They Did This
This is a clinical commentary based on published literature and clinical experience. It describes prescribing trends, FDA approval timelines, and insurance coverage issues for dulaglutide, semaglutide, and tirzepatide. No original data analysis was performed.
Why This Research Matters
GLP-1 drugs are among the most effective diabetes treatments available. When people with diabetes cannot access them because of demand from weight-loss prescribing, it creates a real clinical problem. This tension between obesity treatment and diabetes management has become one of the biggest access issues in modern medicine.
The Bigger Picture
The tension between obesity treatment and diabetes medication access has become one of the biggest pharmaceutical access issues in modern medicine, affecting millions of patients worldwide.
What This Study Doesn't Tell Us
This is a brief commentary, not a systematic study. It does not quantify the extent of shortages or measure patient outcomes from delayed access. The perspectives are from US clinical practice and may not apply globally. The timeline described (2022-2023) is now partially outdated as supply has improved in some areas.
Questions This Raises
- ?Will increased production capacity resolve the shortage?
- ?Should separate supply chains exist for diabetes vs weight loss prescriptions?
Trust & Context
- Key Stat:
- Prior authorization now required Insurance companies began requiring proof of diabetes diagnosis before covering GLP-1 drugs due to off-label weight loss demand
- Evidence Grade:
- Rated preliminary: this is a clinical commentary based on prescribing trends and clinical experience, not a data-driven study.
- Study Age:
- Published in 2024, describing events from 2022–2023. Supply situations have evolved since publication.
- Original Title:
- Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
- Published In:
- Clinical therapeutics, 46(3), 289-292 (2024)
- Authors:
- Powell, Jason, Taylor, James
- Database ID:
- RPEP-09085
Evidence Hierarchy
Frequently Asked Questions
Why is it hard to get Ozempic?
High demand from off-label weight loss prescribing created supply shortages. Insurance companies now often require proof of diabetes diagnosis.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is approved for diabetes, Wegovy for weight loss. They have different doses and insurance coverage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09085APA
Powell, Jason; Taylor, James. (2024). Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.. Clinical therapeutics, 46(3), 289-292. https://doi.org/10.1016/j.clinthera.2023.12.014
MLA
Powell, Jason, et al. "Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.." Clinical therapeutics, 2024. https://doi.org/10.1016/j.clinthera.2023.12.014
RethinkPeptides
RethinkPeptides Research Database. "Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes..." RPEP-09085. Retrieved from https://rethinkpeptides.com/research/powell-2024-use-of-dulaglutide-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.